Medical technology firm Riverain Technologies has received U.S. Food and Drug Administration clearance for a software program that compares current and prior chest X-ray images.
Comparing differences between current and prior chest X-rays of the same patient will help draw clinicians’ attention to what may be an emerging or enlarging tumor, according to a statement from the Dayton, Ohio-area company.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The software aligns two images of the patient and produces a third one that helps radiologists pinpoint subtle changes that show up more clearly than on a traditional X-ray. The software is particularly effective in detecting changes at places in the body where vascular structures and bones come together, Chief Technology Officer Steve Worrell said.
Last month, Riverain received regulatory approval for the next-generation version of its imaging software that “suppresses” bones to help radiologists detect cancerous lung nodules.
The company says its comparison and bone suppression technologies can be paired with its computer-aided detection software to improve early detection of lung cancer.
Last year, Riverain reached a deal with imaging giant Siemens to offer its technology as part of Siemens’ Ysio digital radiography system.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
[Photo from flickr user ServantOfAgape]
